Form 4 for AORT ARTIVION, INC.
Accepted 2025-03-10 00:00:00 ET · period of report 2025-03-06 · accession 0000784199-25-000057 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-03-10 | 2025-03-06 | AORT | Mackin James P | Pres, CEO | S - Sale+OE | $24.77 | -88.4K | 860.4K | -9% | -$2.19M |
| D | 2025-03-10 | 2025-03-06 | AORT | Mackin James P | Pres, CEO | M - OptEx | $21.55 | +75.6K | 936.0K | +9% | +$1.63M |
| D | 2025-03-10 | 2025-03-06 | AORT | Mackin James P | Pres, CEO | A - Grant | $0.00 | +115.7K | 878.1K | +15% | $0 |
| D | 2025-03-10 | 2025-03-06 | AORT | Mackin James P | Pres, CEO | M - OptEx | $0.00 | -75.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-06 | S | D | 70,700 | $24.76 | 865,283 | D | — | — | (F3) The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 30, 2024. (F4) Reflects weighted average price. Range of prices were between $24.40 to $25.10. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2025-03-06 | M | A | 75,615 | $21.55 | 935,983 | D | — | — | (F3) The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 30, 2024. |
| 3 | Common | Common Stock | 2025-03-06 | A | A | 115,701 | $0.00 | 878,107 | D | — | — | (F1) Represents performance stock units granted on February 23, 2024. One third (1/3) were issued on March 6, 2025. The remaining shares earned in connection with the February 2024 grant will be eligible to vest and be issued as follows: one third (1/3) on February 23, 2026; and one third (1/3) on February 23, 2027, assuming employment on the relevant vesting date. |
| 4 | Common | Common Stock | 2025-03-06 | S | D | 17,739 | $24.80 | 860,368 | D | — | — | (F2) These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
| 5 | Derivative | Stock Options (Right to buy) | 2025-03-06 | M | D | 75,615 | $0.00 | 0 | D | $21.55 · 2019-03-12 to 2025-03-12 | 75,615 Common Stock | (F5) Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 12, 2019. |